Ranitidine In Human Plasma Research Articles

Determination of Ranitidine in Human Plasma by SPE and ESI-LC-MS/MS for Use in Bioequivalence Studies

A method for determining ranitidine in human plasma by ESI-LC-MS/MS was validated, using propranolol as internal standard. The extraction method used was solid phase extraction (SPE). Chromatographic separation was performed in a Chromolith C18 (50 mm × 4.6 mm i.d.) analytical column, which provided good separation of ranitidine and propranolol peaks with an analysis time of 2.5 minutes. Extraction yields of 94.4% for ranitidine and 89.4% for the internal standard were obtained. The lower limit of quantification (LLOQ) was 3.00 ng/mL, and limit of detection (LOD) was 0.05 ng/mL, with linearity ranging from 3.00 to 500 ng/mL. The results, thus, showed that this method is suitable for application in bioequivalence studies of ranitidine in human plasma.

A Sensitive and Rapid Determination of Ranitidine in Human Plasma by HPLC with Fluorescence Detection and its Application for a Pharmacokinetic Study

A novel precolumn derivatization reversed-phase high-performance liquid chromatography method with fluorescence detection is described for the determination of ranitidine in human plasma. The method was based on the reaction of ranitidine with 4-fluoro-7-nitrobenzo-2-oxa-1,3-diazole forming yellow colored fluorescent product. The separation was achieved on a C(18) column using methanol-water (60:40, v/v) mobile phase. Fluorescence detection was used at the excitation and emission of 458 and 521 nm, respectively. Lisinopril was utilized as an internal standard. The flow rate was 1.2 mL/min. Ranitidine and lisinopril appeared at 3.24 and 2.25 min, respectively. The method was validated for system suitability, precision, accuracy, linearity, limit of detection, limit of quantification, recovery and robustness. Intra- and inter-day precisions of the assays were in the range of 0.01-0.44%. The assay was linear over the concentration range of 50-2000 ng/mL. The mean recovery was determined to be 96.40 ± 0.02%. This method was successfully applied to a pharmacokinetic study after oral administration of a dose (150 mg) of ranitidine.

Dertermination of Ranitidine in Human Plasma by Solid phase Extraction and HPLC

Objective To make a sensitive method for the determination of ranitidine in human plasma by HPLC-UC. Methods Plasma samples were extracted with C18 Solid phase columns. Chromatograph analysis was carried out with a C18 column and UV Detector which was set at 316 nm. Results Interior impurity in human plasma does not interfere with the determination of ranitidine and internal standard. Good linear relationship(r2=0.999) was obtained in the concentration range from 10.0 to 1000.02%. Conclusion This method is sensitive, selective and simple, is suitable for clinical pharmacokinetic and bioequivalent study of ranitidine. Key words: Ranitidine; HPLC-UV; Bioequivalent

Rapid determination of ranitidine in human plasma by high-performance liquid chromatography without solvent extraction

A simple high-performance liquid chromatographic procedure was developed for the determination of ranitidine in human plasma. The method entailed direct injection of the plasma samples after deproteination using perchloric acid. The chromatographic separation was accomplished with an isocratic elution using mobile phase consisting of 21 m M disodium hydrogen phosphate–triethylamine-acetonitrile (1000:60:150, v/v), pH 3.5. Analyses were run at a flow-rate of 1.3 ml/min using a μbondapak C 18 column and ultraviolet detection at a wavelength of 320 nm. The method was specific and sensitive, with a quantification limit of approximately 20 ng/ml and a detection limit of 5 ng/ml at a signal-to-noise ratio of 3:1. The mean absolute recovery was about 96%, while the within- and between-day coefficient of variation and percent error values of the assay method were all less than 8%. The linearity was assessed in the range of 20–1000 ng/ml plasma, with a correlation coefficient of greater than 0.999. This method has been used to analyze several hundred human plasma samples for bioavailability studies.

Simple high-performance liquid chromatographic method for the determination of ranitidine in human plasma

A simple high-performance liquid chromatographic method was developed for the determination of ranitidine in human plasma. Prior to analysis, ranitidine and the internal standard (metoprolol) were extracted from alkalinized plasma samples using dichloromethane. The mobile phase was 0.05 M potassium dihydrogenphosphate–acetonitrile (88:12, v/v) adjusted to pH 6.5. Analysis was run at a flow-rate of 1.3 ml/min and at a detection wavelength of 229 nm. The method is sensitive with a detection limit of 1 ng/ml at a signal-to-noise ratio of 3:1, while the quantification limit was set at 15 ng/ml. The calibration curve was linear over a concentration range of 15–2000 ng/ml. Mean recovery value of the extraction procedure was about 90%, while the within-day and between-day coefficients of variation and percent error values of the assay method were all less than 15%.

Rapid determination of ranitidine in human plasma by high-performance liquid chromatography

An HPLC method has been developed for the quantification of rantidine in plasma for pharmacokinetic studies. Metoclopramide was used as internal standard. The method uses a simple and rapid sample clean-up procedure involving single-step extraction with organic solvent to extract ranitidine from plasma. After evaporation and reconstitution the samples are chromatographed on a 250 mm×4 mm base-stable reversed-phase column with 0.05 M ammonium acetate-acetonitrile, 75∶25 (v/v) as mobile phase and UV detection at 313 nm. The calibration graph was linear for quantities of ranitidine between 10 and 2000 ng mL−1. Intra- and inter-dayCV did not exceed 11.64%. The quantitation limit was 10 ng mL−1 for human plasma. The applicability of this method for pharmacokinetic studies of ranitidine after oral administration are described. Approximately 90 samples can be processed in 24 h.

Solid-phase extraction and determination of ranitidine in human plasma by a high-performance liquid chromatographic method utilizing midbore chromatography.

An improved high-performance liquid chromatographic (HPLC) method utilizing solid-phase extraction (SPE) and midbore chromatography was developed for the determination of ranitidine in human plasma. A mobile phase of 20 mM K2HPO4-acetonitrile-triethylamine (87.9:12.0:0.1, v/v) pH 6.0 was used with a phenyl analytical column and ultraviolet detection (UV). The method demonstrated linearity from 25 to 1000 ng/ml in 500 microliters of plasma with a detection limit of 10 ng/ml. The method was utilized in a pharmacokinetic study evaluating the effects of pancreatico-biliary secretions on ranitidine absorption.

High Performance Liquid Chromatographic Determination of Ranitidine in Human Plasma

Abstract A rapid reversed phase HPLC method for determination of ranitidine in human plasma has been developed. The procedure involved extraction of the drug from alkalinized plasma spiked with the internal standard (procainamide) using 4% v/v isopropanol in ethylacetate. The extract was evaporated under nitrogen and the residue was reconstituted with methanol and injected onto U-Bondapak C18 column. The mobile phase is 8% v/v acetonitrile in 10 mM potassium phosphate buffer (pH 5.1); at a flow rate of 2.5 ml/min and UV detection at 330 nm. The efficiency of extraction was 90% with a detection limit of 20 ng/ml. The within-day coefficient of variations ranged from 4.09% to 5.81%, whereas those of between-day were from 7.5% to 9.51%.

Rapid and Sensitive Hplc Determination of Ranitidine in Plasma. Application to Pharmacokinetics Study

Abstract A rapid and sensitive reversed-phase high-performance liquid chrormatography (RP-HPLC) method for the separation and quantification of the H2-receptor antagonist drug ranitidine in human plasma is described. The extraction of ranitidine from plasma by an organic solvent was eliminated in this method. Instead, the pre-chromatography isolation of the drug was done by adding approximately 50 mg of zinc sulfate and 200 μL of acetonitrile in 1.0 mL of plasma. A short column packed with pH-stable (1–13) reversed phase PLRP-STM particles was used with an isocratic elution of 5.0mM dibasic potassium phosphate plus 0.50mM tetraethyl ammonium hydroxide/ acetonitrile, 80:20 (v/v). The ranitidine was monitored at 315 nm and 0.20 to 0.002 absorption units full scale (AUFS). The completion time of the assay was less than 15 minutes and had a limit of detection of 1.0 ng/mL for a 100-μL injection volume. After an oral dose of 150 mg of ranitidine, plasma samples were collected at several time points and were analyzed by using this method to determine various pharmacokinetic parameters.

Rapid analysis of ranitidine in biological fluids and determination of its erythrocyte partitioning

A reversed-phase ion-pair high-performance liquid chromatographic assay is described for the rapid and sensitive quantitation of the H 2-receptor antagonist ranitidine in human plasma and urine. The method involves a single-step extraction of the alkalinized sample with methylene chloride and analysis of the evaporated extract on a cyano column. Detection was performed by ultraviolet absorbance monitored at 318 nm. The overall run time of the assay was 5 min at a flow-rate of 2.0 ml/min. The limit of sensitivity was 1 ng/ml ranitidine in human plasma. Urine and plasma samples collected from a subject after administration of an oral dose of 150 mg of ranitidine were analyzed by this method. Furthermore, the procedure was applied to determine the red blood cell partition coefficient of ranitidine in a concentration range up to 10 μg/ml.

Simultaneous Analysis of Cimetidine and Ranitidine in Human Plasma by HPLC

Abstract A rapid method for the simultaneous quantitation of the H2-receptor antagonist drugs cimetidine and ranitidine in human plasma by isocratic ion-pair reverse-phase HPLC is described. The method involves a simple organic extraction step of the alkalinized plasma containing added internal standard followed by back extraction of the extract with dilute acetic acid and subsequent analysis of the aqueous acidic phase on a reverse-phase (C18) column. The eluting solvent was acetonitrile-water (20:80 v/v) containing 0.005 mole/litre octanesulphonic acid and was monitored at 229 nm. The run time for the assay was 12.5 minutes, with a detection limit for cimetidine of 50 ng/m1/(0.2 μmole/1) and that for ranitidine was 20 ng/ml (0.06 umole/1).